Thursday, September 25
17:30-18:00 Industry-supported Meet the Expert Session
Friday, September 26
08:15-08:30 Good Morning Coffee
08:30-08:45 Welcome Note
Congress Co-Chairs
08:45-10:15 Session 1
Controversy: Is there a future for CAR-T cell therapy in T-All?
Moderator: Nicolaus Kröger, Germany
08:45-09:00 Yes: He Huang, China
09:00-09:15 No: Sebastian Giebel, Poland
Controversy: Is survival prolonged if we used CAR-T in second line rather than third-line treatment? 
Moderator: Arnon Nagler, Israel
09:15-09:30 Yes: Anna Sureda, Spain
09:30-09:45 No: Roni Shouval, USA
09:45-10:15 Panel discussion: All session faculty
10:15-10:45 Coffee Break, Poster Viewing and Visit Exhibition
10:45-12:15 Session 2
Controversy: Shall we include venetoclax in the induction chemotherapy and/or conditioning regimen before the transplant?
Moderator: TBA
10:45-11:00 Yes: Thomas Schroeder, Germany
11:00-11:15 No: Jurjen Versluis, Netherlands
Controversy: Should we transplant TP53 multi-hit AML or MDS?
Moderator: Mutlu Arat, Turkey
11:15-11:30 Yes: Coleman Lindsley, USA
11:30-11:45 No: Avichai Shimoni, Israel
11:45-12:15 Panel discussion: All session faculty
12:15-13:15 Session 3
How to treat PTLD post allograft refractory to anti CD20 therapy?
12:15-12:30 By EBV specific T cells: Guenther Koehne, USA
12:30-12:45 By CAR T cells: Marcos de Lima, USA
12:45-13:00 By chemotherapy and DLI: Rafael de la Cámara, Spain
13:00-13:15 Discussion
13:15-14:00 Lunch Break, Poster Viewing and Visit Exhibition
14:00-15:00 Industry-supported Lunch Symposium
15:00-15:45 Session 4
Controversy: Is there a future for immunotherapy in AML outside allogeneic SCT?
Moderator: Charles Craddock, UK
15:00-15:15 Yes: Fabio Ciceri, Italy
15:15-15:30 No: Matthias Stelljes, Germany
15:30-15:45 Discussion
15:45-16:15 Coffee Break, Poster Viewing and Visit Exhibition
16:15-17:45 Session 5
Controversy: Does MRD before allo impact the outcome for MDS?
Moderator: Fernando Barroso Duarte, Brazil
16:15-16:30 Yes: Carmelo Gurnari, Italy
16:30-16:45 No: Arjan van de Loosdrecht, Netherlands
Controversy: Is venetoclax the new partner for 5-Aza in MDS?
Moderator: Arjan van de Loosdrecht, Netherlands
16:45-17:00 Yes: Valeria Santini, Italy
17:00-17:15 No: Moshe Mittelman, Israel
17:15-17:45 Panel discussion: All session faculty
Saturday, September 27
08:30-09:30 Session 6: CME Symposium
Controversy: Are we ready for CAR-T in first-line therapy for MM?
Moderator: Valentín Ortíz-Maldonado, Spain
08:30-08:40 Yes: Maximilian Merz, Germany
08:45-08:50 No: Suzanne Lentzsch, USA
Controversy: BCMA targeted therapy: should we use CAR-Ts first in RRMM?
Moderator: Nico Gagelmann, Germany
08:50-09:00 Yes: Ralph Wäsch, Germany
09:00-09:10 No: TBA
09:10-09:30 Panel discussion: All session faculty
09:30-10:00 Coffee Break, Poster Viewing and Visit Exhibition
10:00-11:00 Industry-supported Symposium
11:00-12:20 Session 7
Controversy: Is PTCy or ATG-based prophylaxis the better haplo approach in AML?
Moderator: Nicolaus Kröger, Germany
11:00-11:15 ATG/ATLG: Xiaojun Huang, China
11:15-11:30 PTCy: Leo Luznik, USA
Controversy: Does HLA matter in HSCT with PTCy?
Moderator: Arnon Nagler, Israel
11:30-11:45 Yes: Katharina Fleischhauer, Germany
11:45-12:00 No: Leslie Kean, USA
12:00-12:20 Panel discussion: All session faculty
12:20-13:00 Lunch Break, Poster Viewing and Visit Exhibition
13:00-14:30 Industry-supported Lunch Symposium
14:30-15:50 Session 8
Controversy: Splenectomy vs spleen irradiation in JAKi resistant MPN patients prior to alloSCT
Moderator: Donal McLornan, UK
14:30-14:45 Pro splenectomy: Nicola Polverelli, Italy
14:45-15:00 Pro spleen irradiation: Nico Gagelmann, Germany
Controversy: Does cord blood provide a stronger GVL effect?
Moderator: Robert Soiffer, USA
15:00-15:15 Yes: Robert Wynn, UK
15:15-15:30 No, stronger GVL with CB: Arnon Nagler, Israel
15:30-15:50 Panel discussion: All session faculty
15:50-16:05 Coffee Break, Poster Viewing and Visit Exhibition
16:05-17:25 Session 9
Controversy: Can modulation of microbiome by diet prevent or treat GvHD?
Moderator: Ernst Holler, Germany
16:05-16:20 Yes: Marcel van den Brink, USA
16:20-16:35 No: Hendrik Poeck, Germany
Controversy: Is fecal transplant the future treatment of SR-GvHD?
Moderator: Marcel van den Brink, USA
16:35-16:50 Yes: Ernst Holler, Germany
16:50-17:05 No: Pavan Reddy, USA
17:05-17:25 Panel discussion: All session faculty
17:25-18:45 Session 10
Controversy: Is there a role for combining JAKi with other agents in acute and chronic GvHD?
Moderator: Francesca Bonifazi, Italy
17:25-17:40 Yes: Hildegard Greinix, Austria
17:40-17:55 No: Olaf Penack, Germany
Controversy: Are MAGIC criteria and biomarker the standard for classifying and treating acute GvHD?
Moderator: Ibrahim Yakoub-Agha, France
17:55-18:10 Yes: James Ferrara, USA
18:10-18:25 No: Amin Alousi, USA
18:25-18:45 Panel discussion: All session faculty
18:45 Poster Walk and Awards Session
(Poster Area)
Sunday, September 28
09:00-10:30 Session 11
Controversy: Can modern technology (e.g. AI) of large registries replace projective phase III studies?
Moderator: Nicolaus Kröger, Germany
09:00-09:15 Yes: Marcelo Pasquini, USA
09:15-09:30 No: Charles Craddock, UK
Controversy: Can we expect CAR-T cells to treat GvHD?
Moderator: Marcelo Pasquini, USA
09:30-09:45 Yes: Chiara Bonini, Italy
09:45-10:00 No: Bruce Blazar, USA
10:00-10:30 Panel discussion: All session faculty
10:30-11:00 Coffee Break
11:00-12:30 Session 12
Controversy: CAR-T vs BITE in autoimmune disease
Moderator: Raffaella Greco, Italy
11:00-11:15 Pro CAR: Dimitrios Mougiakakos, Germany
11:15-11:30 Pro BITE: Tobias Alexander, Germany
Controversy: CAR-T vs BITE in advanced follicular lymphoma
Moderator: TBA
11:30-11:45 Pro CAR: Wolfgang Bethge, Germany
11:45-12:00 Pro BITE: Anna Sureda, Spain
12:00-12:30 Panel discussion: All session faculty
12:30 Closing Remarks
Congress Co-Chairs